Full Product Name
Mouse anti-Human CD55, FITC Conjugated mAb
Product Gene Name
anti-CD55 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Form/Format
Phosphate-buffered solution, pH 7.4, containing 0.09% sodium azide
Experimental Methods
1.Take 100mul peripheral blood anticoagulated by EDTA and add to the bottom of 5ml tube;
2.Add 10mul labeled antibody to the bottom of flow tube mixing with the whole blood, incubate for 20 minutes at room temperature away from light;
3.Add 2 ml1×RBC lysis buffer, incubate for 10 minutes away from light after mixing, dissolve red blood cells (recommended: RBC Lysing Solution 10×);
4.Sample tube is set to 1000 rpm centrifugation for 5 minutes, discard the supernatant;
5.Add 2 ml PBS wash buffer to resuspend the cells, then1000 rpm centrifugation for 5 minutes, discard the supernatant;
6.Add 0.5 ml PBS wash buffer to resuspend the cells and detect by flow cytometry (sample should be determined on the day on the machine and can also be added fixation overnight at 4 degree C then measured).
[PBS wash buffer: PBS +1% FBS +0.1% NaN3]
[Cell fixation: 2% formaldehyde solution]
Preparation and Storage
Store at 4 degree C. DO NOT FREEZE. LIGHT SENSITIVE MATERIAL.
Other Notes
Small volumes of anti-CD55 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-CD55 antibody
4A143-30 reacts with CD55, a 70 kDa GPI anchored single chain glycoprotein, referred to as decay accelerating factor (DAF). CD55 is widely expressed on hematopoietic cells including erythrocytes and NK cells, as well as on some non-hematopoietic cells. DAF protects cells from damage by autologous complement by preventing the amplification steps of the complement components. A defective PIG-A gene can lead to a deficiency of GPI-liked proteins such as CD55 and an acquired hemolytic anemia. This
biological state is called paroxysmal nocturnal hemoglobinuria (PNH). Loss of protective proteins on the cell surface makes the red blood cells of PNH patients sensitive to complement-mediated lysis.
Applications Tested/Suitable for anti-CD55 antibody
Flow Cytometry (FC/FACS), Immunohistochemistry (IHC), Immunofluorescence (IF), Western Blot (WB)(non-reducing)
NCBI/Uniprot data below describe general gene information for CD55. It may not necessarily be applicable to this product.
NCBI Accession #
AAC60633.1
[Other Products]
UniProt Secondary Accession #
P09679; P78361; Q14UF2; Q14UF3; Q14UF4; Q14UF5; Q14UF6; B1AP14; D3DT83; D3DT84; E7ER69[Other Products]
UniProt Related Accession #
P08174[Other Products]
Molecular Weight
59,038 Da
NCBI Official Full Name
CD55, partial
NCBI Official Synonym Full Names
CD55 molecule (Cromer blood group)
NCBI Official Symbol
CD55??[Similar Products]
NCBI Official Synonym Symbols
CR; TC; DAF; CROM; CHAPLE
??[Similar Products]
NCBI Protein Information
complement decay-accelerating factor
UniProt Protein Name
Complement decay-accelerating factor
UniProt Synonym Protein Names
CD_antigen: CD55
Protein Family
Complement decay-accelerating factor
UniProt Gene Name
CD55??[Similar Products]
UniProt Synonym Gene Names
CR; DAF??[Similar Products]
NCBI Summary for CD55
This gene encodes a glycoprotein involved in the regulation of the complement cascade. Binding of the encoded protein to complement proteins accelerates their decay, thereby disrupting the cascade and preventing damage to host cells. Antigens present on this protein constitute the Cromer blood group system (CROM). Alternative splicing results in multiple transcript variants. The predominant transcript variant encodes a membrane-bound protein, but alternatively spliced transcripts may produce soluble proteins. [provided by RefSeq, Jul 2014]
UniProt Comments for CD55
This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829).
Product References and Citations for anti-CD55 antibody
1. Knapp, W et al., eds. (1989) Leucocyte Typing IV: White Cell Differentiation Antigens, Oxford University Press, New York. 2. Makgoba, MW et al., (1988) Nature 331: 86-88. 3. Boyd. AW et al., (1989) Blood 73: 1896-1903.
Research Articles on CD55
1. CD55 rs2564978 polymorphism may contribute to an increased risk of non-small cell lung carcinoma in Chinese population.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
